<DOC>
	<DOCNO>NCT00291343</DOCNO>
	<brief_summary>This study conduct three stage . In DTP booster stage 15 24 month age , subject receive booster dose Tritanrix™-HepB/Hiberix™ . In Mencevax™ ACWY `` full dose '' stage 24 30 month age subject receive dose Mencevax™ ACWY . In Mencevax™ ACWY `` small dose '' stage 30 36 month age , first 75 subject two center test boostability MenA MenC immune response give fifth dose Mencevax™ ACWY vaccine . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Immune Response &amp; Safety GSK Biologicals ' Mencevax™ ACWY Subjects Primed DTPW-HBV=HIB-MENAC-TT-011 Study</brief_title>
	<detailed_description>Subjects group previously prim Tritanrix™-HepB/Hiberix™ control group group previously prim Tritanrix™-HepB/Hib-MenAC . Blood sample draw subject follow : - prior one month full dose Mencevax™ ACWY vaccine . - prior one month 1/5th dose Mencevax™ ACWY vaccine ( first 75 subject two center ) .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Subjects investigator believe parents/guardians comply requirement protocol . A male female , include , 15 24 month age time vaccination . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Having participate primary vaccination study DTPWHBV=HIBMENACTT011 ( eTrack No . 100478 ) Center No . 4328 Center No.4329 . Exclusion criterion : Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede vaccination , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior vaccination . Planned administration/ administration vaccine foreseen study protocol within 30 day vaccination ; exception oral poliovirus vaccine ( OPV ) . Booster vaccination diphtheria , tetanus , pertussis , hepatitis B , Haemophilus influenzae type b ( Hib ) and/or meningococcal serogroups A and/or C disease , date study conclusion visit primary vaccination study DTPWHBV=HIBMENACTT011 ( eTrack No . 100478 ) . History diphtheria , tetanus , pertussis , hepatitis B , Hib and/or meningococcal serogroup A C disease . Known exposure diphtheria , tetanus , pertussis , hepatitis B , Hib and/or meningococcal serogroup A C disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurologic disorder seizure include febrile seizure infancy . Acute disease time enrolment . Planned actual administration immunoglobulins and/or blood product within three month precede Mencevax™ ACWY vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>15 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>hepatitis B</keyword>
	<keyword>meningococcal vaccine</keyword>
	<keyword>pertussis</keyword>
	<keyword>Prophylaxis diphtheria</keyword>
	<keyword>meningococcal serogroups A C disease</keyword>
	<keyword>tetanus</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
</DOC>